ITMCTR1900002557
Not yet recruiting
未知
A multicenter randomized, double-blind, controlled trial for efficacy of YueJu Pills in the treatment of antidepressant
Zhongda Hospital affiliated to Southeast University0 sitesTBD
ConditionsDepression
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- Zhongda Hospital affiliated to Southeast University
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Meet the diagnostic criteria for DSM\-V or ICD\-10 depression;
- •2\. Aged 18\-65 years old;
- •3\. Patients with mild to moderate depression, Hamilton Depression Scale (24 items) score 35 points \= HAMD\-24 \= 20 points;
- •4\. In the past 1 week, there have been no Chinese medicines used to treat depression (including Chinese medicine and decoction), western medicine (fluoxetine, escitalopram, venlafaxine, etc.), or in the short term (3\-5\) Those who have taken the above drugs within days) have been discontinued for more than 7 days;
- •5\. Willing to accept 42 days of treatment, the subject informed consent, and signed informed consent;
- •6\. Both are right\-handed and emmetropia.
Exclusion Criteria
- •1\. Patients with suicidal depression, the score of the third item of Hamilton Depression Scale \= 2 points;
- •2\. People who are suffering from mental illness other than depression, as well as those caused by external environmental disturbances or traumatic brain injury;
- •3\. Pregnant or lactating women;
- •4\. A history of drug allergy;
- •5\. Under 18 years of age or 65 years of age or older;
- •6\. Combined with severe primary diseases such as cardiovascular, pulmonary, liver and kidney and hematopoietic system, and patients with severe brain organic diseases and mental illness;
- •7\. Alcohol and/or psychoactive substances, drug abusers and dependents (including sleeping pills);
- •8\. Does not meet the inclusion criteria, does not use the drug according to the regulations, can not judge the efficacy or incomplete data, affecting the efficacy and safety judgment;
- •9\. Unable to understand scale content due to lack of consciousness, language barriers, and intellectual and cultural level;
- •10\. Left hand;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Early Phase 1
A multicenter, double-blind, randomized controlled trial on the effect of DLTM Formula on the progression of coronary calcification in patients with stable coronary heart diseaseITMCTR2024000060Xiyuan Hospital, China Academy of Chinese Medical Sciences
Recruiting
Phase 2
A multicenter randomized, controlled, double-blinded trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitisautoimmune encephalitisG04Encephalitis, myelitis and encephalomyelitisDRKS00017497Friedrich-Schiller-Universität Jena50
Completed
Not Applicable
A randomized, double-blind, controlled multicenter trial for availability of carbon dioxide insufflation during ERCP for reduction of postprocedure paipancreaticobiliary diseaseJPRN-UMIN000003062Department of Gastroenterology, Hokkaido University Graduate School of Medicine100
Active, not recruiting
Phase 1
A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitisautoimmune encephalitisMedDRA version: 20.0Level: PTClassification code: 10072378Term: Encephalitis autoimmune Class: 100000004852Therapeutic area: Diseases [C] - Immune System Diseases [C20]CTIS2024-514494-21-00Friedrich-Schiller-Universitaet Jena50
Not yet recruiting
Phase 1
A multicenter, randomized controlled, double-blind and double simulated clinical evaluation of gandouling tablet in the treatment of Wilson's diseaseWilson's diaseaseITMCTR2100005333The First Affiliated Hospital of Anhui University of traditional Chinese Medicine